Annuncio pubblicitario
Italia markets closed

  • Dow Jones

    37.900,74
    +165,63 (+0,44%)
     

  • Nasdaq

    15.901,58
    +16,56 (+0,10%)
     

  • Nikkei 225

    38.471,20
    -761,60 (-1,94%)
     

  • EUR/USD

    1,0625
    -0,0001 (-0,01%)
     

  • Bitcoin EUR

    59.027,44
    -624,49 (-1,05%)
     

  • CMC Crypto 200

    885,54
    0,00 (0,00%)
     

  • HANG SENG

    16.248,97
    -351,49 (-2,12%)
     

  • S&P 500

    5.063,36
    +1,54 (+0,03%)
     

NervGen Pharma Grants Stock Options

Newsfile Corp.
·2 minuto per la lettura

Vancouver, British Columbia--(Newsfile Corp. - June 3, 2020) -  NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that the Company has granted 225,000 incentive stock options to Directors, Officers and consultants exercisable at a price of $2.70 per share for a period of five years and that vest equally every three months over a one-year period. In addition, 40,000 incentive stock options were granted to employees exercisable at a price of $2.70 per share for a period of 10 years and that vest equally every six months over a two-year period. All options have been granted in accordance with the policies of the TSX Venture Exchange and the conditions of the Company's stock option plan.

About NervGen

NervGen is restoring life's potential by creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases. The Company is developing drugs for the treatment of spinal cord injury, multiple sclerosis and Alzheimer's disease. NervGen's platform technology targets protein tyrosine phosphatase sigma ("PTPσ"), a neural receptor that impedes nerve repair. Inhibition of the PTPσ receptor has been shown to promote regeneration and remyelination of damaged nerves, as well as improvement of nerve function in animal models for various medical conditions.

ANNUNCIO PUBBLICITARIO

For further information, please contact:

Paul Brennan, President & CEO
pbrennan@nervgen.com

Huitt Tracey, Corporate Communications
htracey@nervgen.com
c: 604.537.2094

Follow NervGen on Twitter (@NervgenC) and LinkedIn (NervGen Pharma Corp.) for the latest news on the Company.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/57199